CVS Health's Aetna Expands 2027 Medicare Advantage Coverage and Enhanced Benefit Options

CVS Health announced Aetna's 2027 Medicare Advantage plan offerings, expanding to 41 states plus Washington, D.C., reaching 57 million eligible beneficiaries. The company is introducing $0 copay options for Tier 1 drugs at preferred pharmacies and expanding specialized plans for chronic conditions into six new states. Processing improvements show over 95% of prior authorization approvals completed within 24 hours, with 82% processed in real time.

CVS Health's Aetna division is broadening its reach in the Medicare Advantage market for 2027, with prescription drug plans now available across nearly the entire country. The insurer is introducing cost-reduction measures, particularly eliminating copayments for commonly prescribed medications at participating pharmacies. Additionally, specialized coverage options designed for beneficiaries managing chronic diseases will extend into new geographic markets, addressing gaps in care coordination for this vulnerable population.

The company has also invested in operational efficiency, demonstrating that the vast majority of approval requests for covered treatments are processed same-day or within a single business day. These processing improvements could reduce delays in patient access to needed medications and services. Complementary initiatives include expanded hospital-transition support programs intended to help members navigate care delivery after discharge.